SCHEMBL728772

SCHEMBL728772

CN(C)CC[CH]CCN(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.41
ALDH1A1 P00352 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
CA12 O43570 1/20 0.41
CA2 P00918 1/20 0.41
CA3 P07451 1/20 0.41
CA4 P22748 1/20 0.41
CA6 P23280 1/20 0.41
CA5A P35218 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
CA5B Q9Y2D0 1/20 0.41
MAPT P10636 2/20 0.39
PRMT3 O60678 1/20 0.35
CARM1 Q86X55 1/20 0.35
PRMT6 Q96LA8 1/20 0.35
PRMT1 Q99873 1/20 0.35
PRMT8 Q9NR22 1/20 0.35
DNM1 Q05193 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5948492 0.87
SCHEMBL1417224 0.85 ALDH1A1 (0.53) TSHRALDH1A1TDP1CA12CA2
SCHEMBL27310498 0.85
SCHEMBL5749958 0.83 ALDH1A1 (0.35) TSHRALDH1A1TDP1CA12CA2
SCHEMBL2188530 0.83
SCHEMBL5948814 0.83 DNM1 (0.48) TSHRALDH1A1TDP1CA12CA2
SCHEMBL28624640 0.81
Hydrochloric Acid SCHEMBL28074436 0.81
SCHEMBL5948738 0.81 DNM1 (0.52) TSHRALDH1A1DNM1
SCHEMBL27937461 0.79 ALDH1A1 (0.53) TSHRALDH1A1TDP1CA12CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10023863-B2 Therapeutics with conformationally restricted monomers MARINA BIOTECH, INC. (US) 2018-07-17 US disclosed
US-9751909-B2 Synthesis and uses of nucleic acid compounds with conformationally restricted monomers MARINA BIOTECH, INC. (US) 2017-09-05 US disclosed
WO-2017115329-A1 C-3 NOVEL TRITERPENONE DERIVATIVES AS HIV INHIBITORS HETERO RESEARCH FOUNDATION (IN) 2017-07-06 WO disclosed
US-20150315591-A1 NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF MARINA BIOTECH, INC. (US) 2015-11-05 US disclosed
US-20150284717-A1 OLIGOMERS WITH CONFORMATIONALLY RESTRICTED MONOMERS AND UNLOCKED NUCLEOMONOMERS MARINA BIOTECH INC (US) 2015-10-08 US disclosed
US-20150258130-A1 NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF MARINA BIOTECH, INC. (US) 2015-09-17 US disclosed
US-20150259686-A1 NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF MARINA BIOTECH, INC. (US) 2015-09-17 US disclosed
US-9074205-B2 Nicked or gapped nucleic acid molecules and uses thereof MARINA BIOTECH, INC. (US) 2015-07-07 US disclosed
US-20150080564-A1 SYNTHESIS AND USES OF NUCLEIC ACID COMPOUNDS WITH CONFORMATIONALLY RESTRICTED MONOMERS MARINA BIOTECH, INC. (US) 2015-03-19 US disclosed
US-20130190383-A1 NUCLEIC ACID COMPOUNDS WITH CONFORMATIONALLY RESTRICTED MONOMERS AND USES THEREOF MARINA BIOTECH, INC. (US) 2013-07-25 US disclosed
EP-1210088-A1 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF HERPES SIMPLEX VIRUS G.D. SEARLE & CO. (US) 2002-06-05 EP disclosed
US-6380189-B1 FOR TREATING HERPES-RELATED DISORDERS G.D. SEARLE & CO. 2002-04-30 US disclosed
EP-0828721-B1 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS SEARLE & CO (US) 2001-11-14 EP disclosed
EP-1122245-A2 2-Amino-benzoxazinones for the treatment of viral infections G.D. Searle & Co. (US) 2001-08-08 EP disclosed
WO-2001003697-A1 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF HERPES SIMPLEX VIRUS G.D. SEARLE & CO. (US) 2001-01-18 WO disclosed
US-5985872-A THERAPEUTIC TREATMENT OF HERPES VIRAL INFECTION G.D. SEARLE & CO. (US) 1999-11-16 US disclosed
EP-0659761-B1 New 17-iminomethylalkenyl-5beta-14beta-androstane and 17-iminoalkyl-5beta-14beta-androstane derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same SIGMA TAU IND FARMACEUTI (IT) 1998-04-22 EP disclosed
EP-0828721-A1 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS G.D. SEARLE & CO. (US) 1998-03-18 EP disclosed
WO-1996037485-A1 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS G.D. SEARLE & CO. (US) 1996-11-28 WO disclosed
EP-0659761-A2 New 17-iminomethylalkenyl-5beta-14beta-androstane and 17-iminoalkyl-5beta-14beta-androstane derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing same Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) 1995-06-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150315591-A1 NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF RNMT, POLRMT, SNRPE TSHR 3574/4885ALDH1A1 3495/4885TDP1 366/4885
US-20150080564-A1 SYNTHESIS AND USES OF NUCLEIC ACID COMPOUNDS WITH CONFORMATIONALLY RESTRICTED MONOMERS POLN, NSUN2, POLM TSHR 1987/4885ALDH1A1 4544/4885TDP1 1249/4885
US-20150258130-A1 NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF RNMT, POLRMT, SNRPE TSHR 3574/4885ALDH1A1 3495/4885TDP1 366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.